Indivior Pharmaceuticals, Inc. (INDV)
34.28
-0.23
(-0.67%)
USD |
NASDAQ |
Sep 11, 13:45
Indivior Pharmaceuticals Gross Profit (TTM) : 1.116B for June 30, 2026
Gross Profit (TTM) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Gross Profit (TTM) Data
| Date | Value |
|---|---|
| June 30, 2026 | 1.116B |
| March 31, 2026 | 1.073B |
| December 31, 2025 | 1.018B |
| September 30, 2025 | 974.00M |
| June 30, 2025 | 963.00M |
| March 31, 2025 | 933.00M |
| December 31, 2024 | 957.00M |
| September 30, 2024 | 946.00M |
| June 30, 2024 | 924.00M |
| March 31, 2024 | 927.00M |
| December 31, 2023 | 891.00M |
| September 30, 2023 | 847.00M |
| June 30, 2023 | 816.00M |
| March 31, 2023 | 772.00M |
| December 31, 2022 | 729.00M |
| September 30, 2022 | 715.00M |
| June 30, 2022 | 684.00M |
| March 31, 2022 | 671.00M |
| December 31, 2021 | 649.00M |
| September 30, 2021 | 621.00M |
| June 30, 2021 | 592.00M |
| March 31, 2021 | 553.00M |
| December 31, 2020 | 539.00M |
| Date | Value |
|---|---|
| September 30, 2020 | 471.00M |
| June 30, 2020 | 503.00M |
| March 31, 2020 | 561.00M |
| December 31, 2019 | 627.00M |
| September 30, 2019 | 739.00M |
| June 30, 2019 | 786.00M |
| March 31, 2019 | 831.00M |
| December 31, 2018 | 862.00M |
| September 30, 2018 | 894.00M |
| June 30, 2018 | 930.00M |
| March 31, 2018 | 961.00M |
| December 31, 2017 | 977.00M |
| September 30, 2017 | 976.00M |
| June 30, 2017 | 975.00M |
| March 31, 2017 | 949.00M |
| December 31, 2016 | 936.00M |
| September 30, 2016 | 917.00M |
| June 30, 2016 | 894.00M |
| March 31, 2016 | 895.00M |
| December 31, 2015 | 885.00M |
| September 30, 2015 | 676.00M |
| June 30, 2015 | 457.00M |
| March 31, 2015 | 221.00M |
Gross Profit Definition
Annual, Interim and Preliminary Items - Commercial, Other Financial Companies
Gross Profit (TTM) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Gross Profit (TTM) Benchmarks
| Supernus Pharmaceuticals, Inc. | 629.69M |
| Liquidia Corp. | 416.18M |
| Corcept Therapeutics, Inc. | 816.73M |
| Harrow, Inc. | 201.96M |
| Collegium Pharmaceutical, Inc. | 485.09M |